Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Blood (2019) 134 (Supplement_1): 140.
Currently there are no citedby results. Try again later.
